z-logo
open-access-imgOpen Access
Mortality Results from a Randomized Prostate-Cancer Screening Trial
Author(s) -
Gerald L. Andriole,
E. David Crawford,
Robert L. Grubb,
Saundra S. Buys,
David Chia,
Timothy R. Church,
Mo. Fouad,
Edward P. Gelmann,
Paul A. Kvale,
Douglas J. Reding,
Joel L. Weissfeld,
Lance Yokochi,
Barbara O’Brien,
Jonathan D. Clapp,
Joshua M. Rathmell,
Thomas L. Riley,
Richard B. Hayes,
Barnett S. Kramer,
Grant Izmirlian,
Anthony B. Miller,
Paul F. Pinsky,
Philip C. Prorok,
John K. Gohagan,
Christine D. Berg
Publication year - 2009
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa0810696
Subject(s) - medicine , rectal examination , prostate cancer , randomized controlled trial , prostate , oncology , prostate specific antigen , prostate cancer screening , colorectal cancer , cancer , gynecology
The effect of screening with prostate-specific-antigen (PSA) testing and digital rectal examination on the rate of death from prostate cancer is unknown. This is the first report from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial on prostate-cancer mortality.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom